Skip to main content
Premium Trial:

Request an Annual Quote

DNAVision to Offer Ipsogen's Breast Cancer Tests

NEW YORK (GenomeWeb News) - Ipsogen said today it has inked a pact with DNAVision that allows DNAVision to offer tests based on Ipsogen’s breast cancer gene profiles in a CLIA environment.
 
Ipsogen has a portfolio of diagnostics for blood cancers that are registered in Europe as IVDs. The company said that the agreement with DNAVision enables it to launch “a new generation of IVD profiling diagnostic products addressing unmet needs in guiding breast cancer therapies.”
 
DNAVision will offer Ipsogen’s microarray profiling services “at the level of quality of quantitative PCR,” Ipsogen said.
 
Financial terms of the agreement were not released.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.